Table 3.

Log rank test on OS for categorical variables (n=209) (CI denotes confidence interval; *primary site by Siewert's classification³⁰; staging by AJCC 6^th Edition³⁷.

Level	Frequency (%)	Median OS time (95 % CI) (month)	P-value
Primary Site*
Esophagus	50 (23.9)	20.36 (16.05, NA)	0.173
AEG 1	93 (44.5)	18.82 (15.3, 23.78)
AEG 2	61 (29.2)	33.39 (20.07, NA)
AEG 3	5 (2.4)	20.43 (6.51, NA)
Tumor Status
T1	10 (4.8)	39.05 (39.05, NA)	0.001
T2	17 (8.1)	NA (34.44, NA)
T3	166 (79.4)	20.30 (17.11, 23.78)
T4	14 (6.7)	15.53 (12.27, NA)
TX	2 (1.0)	7.73 (6.58, NA)
Lymph Node Status
N0	61 (29.2)	37.47 (25.76, NA)	0.007
N+	146 (69.9)	18.91 (15.53, 21.71)
NX	2 (1.0)	11.10 (9.7, NA)
Metastatic Status
M0	161 (77.0)	21.02 (17.17, 27.7)	0.773
M1A	22 (10.5)	23.98 (18.82, NA)
M1B	26 (12.4)	17.80 (14.74, NA)
Stage
I	8 (3.8)	39.05 (39.05, NA)	0.006
IIA	48 (23.0)	37.47 (25.76, NA)
IIB	9 (4.3)	43.26 (34.44, NA)
III	96 (45.9)	14.90 (13.12, 20.3)
IVA	22 (10.5)	23.98 (18.82, NA)
IVB	26 (12.4)	17.80 (14.74, NA)
Tumor Histology
Adenocarcinoma	158 (75.6)	21.02 (18.82, 27.73)	0.744
Squamous cell carcinoma	51 (24.4)	19.70 (15.53, NA)
Tumor Grade
G1 well diff.	2 (1.0)	3.37 (1.48, NA)	<0.0001
G2 moderately diff.	96 (45.9)	34.44 (21.78, NA)
G3 poorly diff.	110 (52.6)	19.93 (14.87, 21.71)
GX undetermined	1 (0.5)	23.78 (NA, NA)
Induction chemotherapy
Yes	84 (40.2)	18.82 (16.05, 27.7)	0.984
No	125 (59.8)	21.78 (19.8, 34.44)
Chemoradiotherapy Agents
Platinum + Fluoropyrimidine	56 (26.8)	21.02 (17.17, 43.26)	0.197
Taxane + Fluoropyrimidine	115 (55.0)	22.50 (19.93, 35.66)
Others	34 (16.3)	17.07 (14.01, NA)
Unknown	4 (1.9)	8.29 (7.34, NA)
Clinical CR after chemoradiation
Achieved	130 (68.8)	37.47 (27.14, NA)	<0.0001
Not achieved	59 (31.2)	12.6 (9.7, 17.17)
iSUV (dichotomized)
< 12.7 (median)	89 (49.4)	33.39 (21.71, NA)	0.002
>= 12.7 (median)	91 (50.6)	17.11 (12.27, 23.78)